



Supporting Information

for

Synthesis and biological profile of 2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridines, a novel class of acyl-ACP thioesterase inhibitors

Jens Frackenpohl, David M. Barber, Guido Bojack, Birgit Bollenbach-Wahl, Ralf Braun, Rahel Getachew, Sabine Hohmann, Kwang-Yoon Ko, Karoline Kurowski, Bernd Laber, Rebecca L. Mattison, Thomas Müller, Anna M. Reingruber, Dirk Schmutzler and Andrea Svejda

Beilstein J. Org. Chem. **2024**, *20*, 540–551. doi:10.3762/bjoc.20.46

General synthetic procedures, characterization of all target compounds, methods for biological and biochemical testing, and scans of ^1H and ^{13}C NMR spectra of the new 2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridines

1.	Chemistry	S2
1.1.	General information	S2
1.2.	General synthetic procedures and characterization	S2
1.2.1.	General procedure for the synthesis of 6-bromo-5-2,3-dihydro[1,3]thiazolo[4,5- <i>b</i>]pyridines 13a–c	S2
1.2.2.	Characterization of 6-bromo-5-2,3-dihydro[1,3]thiazolo[4,5- <i>b</i>]pyridines 13a–c	S3
1.2.3.	General procedure for the synthesis of substituted 6-methyl-2,3- dihydro[1,3]thiazolo[4,5- <i>b</i>]pyridines 7a–c	S20
1.2.4.	Characterization of substituted 6-methyl-2,3-dihydro[1,3]thiazolo[4,5- <i>b</i>]pyridines 7a–c	S20
1.2.5.	General procedure for the synthesis of N-acylated 6-bromo-2,3- dihydro[1,3]thiazolo[4,5- <i>b</i>]pyridines 14a–c	S30
1.2.6.	Characterization of N-acylated 6-bromo-2,3-dihydro[1,3]thiazolo[4,5- <i>b</i>]pyridines 14a–c	S30
1.2.7.	General procedure for the synthesis of N-acylated 6-methyl-2,3- dihydro[1,3]thiazolo[4,5- <i>b</i>]pyridines 16a–f	S39
1.2.8.	Characterization of N-acylated 6-methyl-2,3-dihydro[1,3]thiazolo[4,5- <i>b</i>]pyridines 16a–f	S39
1.2.9.	Characterization of borylated compounds 17a–e and side product 17f	S57
2.	Biology and biochemistry	S67
2.1.	In vivo greenhouse screening	S67
2.2.	Biochemistry	S68
2.2.1.	<i>LpFAT A</i> expression and purification	S68
2.2.2.	<i>LpFAT A</i> fluorescence polarization assay	S68
3.	References	S68

1. Chemistry

1.1. General information

All reagent-grade solvents and chemicals were purchased from standard commercial suppliers and used without further purification. All nonaqueous reactions were carried out under anhydrous conditions using dry solvents. Reactions were monitored by LC–MS or TLC carried out on 0.25 mm silica gel plates (60F-254). TLC plates were visualized using UV light. Yields refer to spectroscopically pure compounds unless otherwise stated. Flash column chromatography was carried out with a Biotage Isolera™ using CHROMABOND® Flash SiOH (Macherey-Nagel) columns in sizes ranging from 15 g to 120 g. The ¹H NMR, ¹³C NMR and ¹⁹F NMR spectroscopy data that are reported for the chemical examples described (400 and 600 MHz for ¹H NMR and 150 MHz for ¹³C NMR and 375 MHz for ¹⁹F NMR, solvent: CDCl₃, CD₃OD or *d*₆-DMSO, internal standard: tetramethylsilane δ = 0.00 ppm), were recorded using a Bruker AVII spectrometer with a Bruker TBI-probe, and the signals listed have the following meanings: br = broad; s = singlet, d = doublet, t = triplet, dd = doublet of doublets, ddd = doublet of a doublet of doublets, m = multiplet, q = quartet, quint = quintet, sext = sextet, sept = septet, dq = doublet of quartets, dt = doublet of triplets. The abbreviations used for chemical groups are defined as follows: Me = CH₃, Et = CH₂CH₃, *t*-Hex = C(CH₃)₂CH(CH₃)₂, *t*-Bu = C(CH₃)₃, *n*-Bu = unbranched butyl, *n*-Pr = unbranched propyl, c-Hex = cyclohexyl, ArH = aromatic hydrogen, *Het*H = heteroaromatic hydrogen. High resolution mass spectrometry (HRMS) was conducted using a Waters spectrometer with Q-ToF Premiers using electron spray ionization (ESI).


1.2. General synthetic procedures and characterization

1.2.1. General procedure for the synthesis of 6-bromo-5-2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridines 13a–c

To a stirred mixture of 6-bromopyridin-2-amine (**8**, 1.00 equiv), a phenylboronic acid (1.16 equiv), and Na₂CO₃ (2.00 equiv) in a mixture of 1,4-dioxane and water (1:1), Pd(dppf)Cl₂ (0.04 equiv) were added and stirred together at room temperature, before the mixture was stirred at 80 °C for 3 h. Thereafter, the reaction mixture was cooled to room temperature, diluted with water and extracted thoroughly with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The remaining residue was purified via column chromatography (gradient ethyl acetate/heptane) to afford the desired 6-phenylpyridin-2-amine **9**. The corresponding 6-phenylpyridin-2-amine **9** (1.0 equiv) was dissolved in acetonitrile and cooled to 0 °C. Thereafter, *N*-bromosuccinimide (2.2 equiv) was added carefully. The reaction mixture was warmed to room temperature and stirred for 4 h. Subsequently, the reaction mixture was diluted with water and the resulting solid was filtered off. The solid was washed thoroughly with water and dried to afford the corresponding 3,5-dibromo-6-phenylpyridin-2-amine **10**. To a stirred solution of a 3,5-dibromo-6-phenylpyridin-2-amine **10** (1.0 equiv) in *N,N*-dimethylformamide was added potassium *O*-ethyl dithiocarbonate (2.2 equiv) under an argon atmosphere at room temperature. The resulting mixture was heated under reflux conditions for 7 h. Thereafter, the reaction mixture was cooled to room temperature, poured onto ice water and acidified carefully with 2 N HCl. The obtained precipitate was filtered off, washed with water, collected and dried under reduced pressure to afford the corresponding 6-bromo-5-phenyl[1,3]thiazolo[4,5-*b*]pyridine-2-thiol and 6-bromo-5-(2-fluorophenyl)[1,3]thiazolo[4,5-*b*]pyridine-2(*3H*)thione thiol–thione tautomer **11**. As IUPAC naming tools have afforded thiols as preferred names we have opted to use the thiol naming throughout the Supporting Information. However, several spectra indicate that the thiones are the preferred tautomer in the CDCl₃ solution when


measuring the NMR spectra. In the next step, the corresponding 6-bromo-5-phenyl[1,3]thiazolo[4,5-*b*]pyridine-2-thiol **11** (1.0 equiv) was dissolved in acetic acid, and iron powder (15 equiv) was added carefully in portions. The resulting reaction mixture was stirred at a temperature of 100 °C for 10 h. After full conversion (indicated by LC–MS), the reaction mixture was cooled to 60 °C, and the iron powder was filtered off. The remaining solution was diluted with water, and the resulting precipitate was filtered, washed with water and dried under reduced pressure. The remaining crude residue was redissolved in dichloromethane, then water was added, followed by thorough extraction using dichloromethane. The combined organic layers were dried over anhydrous MgSO₄, filtered and dried under reduced pressure. The remaining residue was purified via column chromatography (gradient ethyl acetate/heptane) to afford the corresponding 6-bromo-5-phenyl[1,3]thiazolo[4,5-*b*]pyridine **12**. The 6-bromo-5-phenyl[1,3]thiazolo[4,5-*b*]pyridine **12** (3.07 mmol, 1.0 equiv) was dissolved in absolute toluene (10 mL) in a flame-dried round-bottom flask under argon. Ammonia borane (285 mg, 9.20 mmol, 3.0 equiv) and B(C₆F₅)₃ (79 mg, 0.15 mmol, 0.05 equiv) were added to the solution and the resulting reaction mixture was stirred at a temperature of 45 °C for 5 h and concentrated thereafter under reduced pressure. The remaining residue was redissolved in acetonitrile, formic acid was added, and the reaction mixture was stirred at room temperature for 2 h. The phases were separated via phase separator and the organic layer was concentrated under reduced pressure. The remaining crude product was purified via column chromatography (gradient ethyl acetate/hexane) to afford the desired substituted 6-bromo-2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridine **13a–c**.

1.2.2. Characterization of 6-bromo-5-2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridines **13a–c**



13a

6-Bromo-5-phenyl-2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridine (**13a**, 700 mg, 70%). ¹H NMR (600 MHz, CDCl₃): δ 4.56 (s, 2H), 6.47–6.53 (m, 1H), 7.32–7.34 (m, 1H), 7.35–7.39 (m, 1H), 7.40–7.44 (m, 2H), 7.52–7.55 (m, 2H) ppm; ¹³C NMR (CDCl₃, 151 MHz): δ 49.0 (CH₂), 106.5 (C), 122.3 (C), 128.0 (CH), 128.2 (CH), 129.2 (CH), 131.8 (CH), 139.7 (C), 150.9 (C), 159.9 (C) ppm; HRMS (ESI, *m/z*): calcd. for C₁₂H₁₀N₂SBr, 292.9735 [M+H]⁺; found 292.9748.



7.54
7.54
7.53
7.53
7.43
7.43
7.42
7.42
7.41
7.41
7.40
7.40
7.38
7.38
7.37
7.37
7.36
7.36
7.36
7.35
7.33
7.27
7.26
6.50

5.30

4.56

3.49

1.55


10.00
10.00
10.00
10.00

Current Data Parameters
NAME 079812
EXPNO 10
PROCNO 1

F2 - Acquisition Parameters
Date_ 20231101
Time_ 13.11 h
INSTRUM Avance Neo
PROBHD Z162398_0004 (1
PULPROG zg30
TD 131072
SOLVENT CDCl3
NS 800
DS 0
SWH 15625.000 Hz
FIDRES 0.238419 Hz
AQ 4.1943040 sec
RG 327.000
DE 10.00 usec
TE 298.1 K
D1 1.00000000 sec
TD0 1
SFO1 600.3357031 MHz
P1 2.60 usec
PO 7.80 usec
PL 5.56960011 W


F2 - Processing Parameters
SI 131072
SF 600.3357031 MHz
WDW EM
SSB 0
LB 0.20 Hz
GB 0
EC 4.00

TMS linewidth: 1.01 Hz




Scale: 6.602 ppm/cm, 998.5 Hz/cm

Current Data Parameters
NAME 079812
EXPNO 11
PROCNO 1
F2 - Acquisition Parameters
Date_ 20231001
Time 15:25 h
INSTRUM Avance Neo
PROBHD Z162398.0004 (1
PULPROG zgpg30
PCPDPR 131172
SOLVENT CDCl3
NS 2048
DS 0
SWH 35714.285 Hz
FIDRES 0.044457 Hz
AQ 1.635080 sec
RG 101
DW 14.000 usec
DE 18.00 usec
DI 2.0000000 K sec
D1 0.03000000 sec
TD0 1
SF01 150.9697222 MHz
NUC1 13C
PC 4.00 usec
P1 12.00 usec
PLW1 117.1900244 W
SF02 600.3324013 MHz
NUC2 1H
PCPDPR 131172
PCPDPR 80.00 usec
PLW2 5.55999994 W
PLW12 0.05560000 W
PLW13 0.02792200 W
F2 - Processing parameters
SI 131072
SF 150.953980 MHz
WDW EM
SSB 0 Hz
GB 1.0 Hz
PC 1.40




13b


Representative procedure for the synthesis of 6-bromo-5-(2-fluorophenyl)-2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridine (13b): To a stirred mixture of 6-bromopyridin-2-amine (**8**, 10.00 g, 56.88 mmol, 1.00 equiv), 2-fluorophenylboronic acid (9.52 g, 65.98 mmol, 1.16 equiv), and Na₂CO₃ (12.06 g, 113.8 mmol, 2.00 equiv) in a mixture of 1,4-dioxane (80 mL) and water (80 mL) at room temperature was added Pd(dppf)Cl₂ (1.67 g, 2.28 mmol, 0.04 equiv), and the mixture was stirred at 80 °C for 3 h. Thereafter, the reaction mixture was cooled to room temperature, diluted with water, and extracted thoroughly with ethyl acetate. The combined organic layer was washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The remaining residue was purified via column chromatography (gradient ethyl acetate/hexane) to afford 6-(2-fluorophenyl)pyridin-2-ylamine (**9b**, 9.98 g, 93%). ¹H NMR (400 MHz, CDCl₃): δ_H 7.92-7.88 (m, 1H), 7.53-7.49 (m, 1H), 7.36-7.31 (m, 1H), 7.25-7.20 (m, 1H), 7.16-7.10 (m, 1H), 6.50-6.48 (d, 1H), 4.53-4.44 (br. s, 2H, NH₂).




6-(2-Fluorophenyl)pyridin-2-ylamine (**9b**, 9.98 g, 52.49 mmol, 1.0 equiv) was dissolved in acetonitrile (140 mL) and cooled to 0 °C. Thereafter, *N*-bromosuccinimide (20.56 g, 115.49 mmol, 2.2 equiv) was added carefully. The reaction mixture was warmed to room temperature and stirred for 4 h. Subsequently, the reaction mixture was diluted with water, and the resulting solid was filtered off. The



6-Bromo-5-(2-fluorophenyl)[1,3]thiazolo[4,5-*b*]pyridine (**12b**, 1,000 mg, 3.07 mmol, 1.0 equiv) was dissolved in absolute toluene (10 mL) in an oven-dried round-bottom flask under argon, to which ammonia borane (285 mg, 9.20 mmol, 3.0 equiv) and B(C₆F₅)₃ (79 mg, 0.15 mmol, 0.05 equiv) were added. The resulting reaction mixture was stirred at a temperature of 45 °C for 5 h and then concentrated under reduced pressure. The remaining residue was redissolved in acetonitrile, formic acid was added, and the reaction mixture was stirred at room temperature for 2 h. The phases were separated via phase separator, and the organic layer was concentrated under reduced pressure. The remaining crude product was purified via column chromatography (gradient ethyl acetate/hexane) to afford 6-bromo-5-(2-fluorophenyl)-2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridine (**13b**, 596 mg, 59%). ¹H NMR (600 MHz, CDCl₃): δ 4.56 (s, 2H), 6.88 (brs, 1H), 7.11–7.16 (m, 1H), 7.21 (td, *J* = 7.5, 1.1 Hz, 1H), 7.31 (s, 1H), 7.34 (td, *J* = 7.4, 1.9 Hz, 1H), 7.36–7.41 (m, 1H) ppm; ¹³C NMR (CDCl₃, 151 MHz): δ 49.0 (CH₂), 108.1 (C), 115.7 (CH), 115.9 (CH), 123.5 (C), 124.0 (CH), 127.7 (d, C), 130.4 (CH), 131.1 (CH), 146.2 (C), 158.7 (C), 160.3 (d, C) ppm; HRMS (ESI, *m/z*): calcd. C₁₂H₉BrFN₂S, 310.9671 [M+H]⁺; found 310.9654.





Current Data Parameters
 NAME 079810
 EXPNO 11
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20231020
 Time 14:51 h
 Name_ 20231020
 PROBRD 2162398.0004
 PULPROG zgpg30
 TD 65536
 SOLVENT CDCl3
 NS 2048
 DS 4
 SWH 35714.285 Hz
 FIDRES 1.089913 Hz
 AQ 0.9175040 sec
 RG 101
 RW 14.400 usec
 DB 14.400 usec
 TE 298.1 K
 CNST2 145.0000000
 D1 2.00000000 sec
 D2 0.0034828 sec
 D3 0.0002000 sec
 D16 0.0002000 sec
 TD0 1
 SF01 150.9697225 MHz
 NU01 13C
 P13 12.00 usec
 P14 2000.00 usec
 P15 0 W
 P16 117.19000244 W


SENAME[5] C1760comp.4
 SEADJ5 0.500 Hz
 SEADJ5 25.7849985 W
 SEW5 600.3324013 MHz
 NUC2 1H
 NUC2 1.5000000
 CNST12 1.5000000
 P12 12.00 usec
 P13 12.00 usec
 P14 8.00 usec
 P4 16.00 usec
 P4 80.00 usec
 FID2 5.5599994 W
 FID2 0.5555556 W
 GPRM[1] 31.00 %
 GPRM[2] 31.00 %
 GPRM[3] 31.00 %
 GPRM[4] 31.00 %
 P16 1000.00 usec

F2 - Processing parameters
 SI 32768
 SF 150.955078 MHz
 WDW 0
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40

^1H NMR (400 MHz, CDCl_3) and LC–MS spectra of a second batch within the preparation of **13b**:


3: UV Detector: TIC

1.681e+2
Range: 1.672e+2





Peak ID Time Mass Found
1 1.46 310.96
1: (Time: 1.46) Combine (192:199-167:180)


1:MS ES+
6.0e+007



Peak ID Time Mass Found
1 1.46 308.96
1: (Time: 1.46) Combine (192:198-166:180)


2:MS ES-
2.0e+005






13c

Representative procedure for the synthesis of 6-bromo-5-(2-methylphenyl)-2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridine (13c): To a stirred mixture of 6-bromopyridin-2-amine (**8**, 15.00 g, 86.69 mmol, 1.00 equiv), 2-methylphenylboronic acid (23.58 g, 173.39 mmol, 2.00 equiv) and K₂CO₃ (23.96 g, 173.39 mmol, 2.00 equiv) in a mixture of 1,4-dioxane (160 mL) and water (160 mL) at room temperature was added Pd(dppf)Cl₂ (3.17 g, 4.34 mmol, 0.05 equiv) and the mixture was stirred at 80 °C for 3 h. Thereafter, the reaction mixture was cooled to room temperature, diluted with water and extracted thoroughly with ethyl acetate. The combined organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The remaining residue was purified via column chromatography (gradient ethyl acetate/hexane) to afford 6-(2-methylphenyl)pyridin-2-amine (**9c**, 9.40 g, 59%). ¹H NMR (400 MHz, CDCl₃): δ_H 7.51-7.49 (m, 1H), 7.37-7.34 (m, 1H), 7.30-7.23 (m, 2H), 6.74-6.72 (m, 1H), 6.48-6.44 (m, 1H), 4.52-4.46 (br. s, 2H, NH₂), 2.35 (s, 3H).




6-(2-Methylphenyl)pyridin-2-amine (**9c**, 8.97 g, 48.20 mmol, 1.0 equiv) was dissolved in acetonitrile (140 mL) and cooled to 0 °C. Thereafter, *N*-bromosuccinimide (18.87 g, 106.04 mmol, 2.2 equiv) was added carefully. The reaction mixture was warmed to room temperature and stirred for 2 h.


Subsequently, the reaction mixture was diluted with water and the resulting solid was filtered off. The solid was washed thoroughly with water and dried to afford compound 3,5-dibromo-6-(2-methylphenyl)pyridin-2-ylamine (**10c**, 13.10 g, 79%) as an orange solid. ^1H NMR (400 MHz, CDCl_3): δ_{H} 7.91 (s, 1H), 7.33-7.27 (m, 3H), 7.20-7.17 (m, 1H), 5.04-4.96 (br. s, 2H, NH_2), 2.18 (s, 3H). The reaction was repeated on the same scale to afford 26.17 g of **10c** in total



To a stirred solution of 3,5-dibromo-6-(2-methylphenyl)pyridin-2-amine (**10c**, 26.17 g, 76.50 mmol, 1.0 equiv) in *N,N*-dimethylformamide (120 mL) at room temperature was added potassium *O*-ethyl dithiocarbonate (27.81 g, 168.31 mmol, 2.2 equiv). The resulting mixture was heated under reflux conditions for 6.5 h. Thereafter, the reaction mixture was cooled to room temperature, poured onto ice water and acidified with 2 N HCl. The obtained precipitate was filtered, washed with water, collected and dried under reduced pressure to afford the 6-bromo-5-(2-methylphenyl)[1,3]thiazolo[4,5-*b*]pyridine-2-thiol and 6-bromo-5-(2-methylphenyl)[1,3]thiazolo[4,5-*b*]pyridine-2(3*H*)-thione thiol–thione tautomer **11c** (25.00 g, 97%). ^1H NMR (400 MHz, CDCl_3): δ_{H} 9.72 (br. s, 1H), 8.01 (s, 1H), 7.37-7.35 (m, 1H), 7.33-7.29 (m, 2H), 7.21-7.19 (m, 1H), 2.16 (s, 3H).




6-Bromo-5-(2-methylphenyl)[1,3]thiazolo[4,5-*b*]pyridine-2-thiol (**11c**, 26.81 g, 79 mmol, 1.0 equiv) was dissolved in acetic acid (350 mL), and iron powder (55.49 g, 994 mmol, 15 equiv) was added carefully in portions. The resulting reaction mixture was stirred at a temperature of 100 °C for 8 h. After full conversion (indicated by LC–MS), the reaction mixture was cooled to 60 °C, and the iron powder was filtered off. The remaining solution was diluted with water, and the resulting precipitate was filtered, washed with water and dried under reduced pressure. The remaining crude residue was redissolved in dichloromethane, then water was added, followed by thorough extraction. The combined organic layer was dried over magnesium sulfate, filtered and dried under reduced pressure. The remaining residue was purified via column chromatography (gradient ethyl acetate/hexane) to afford 6-bromo-5-(2-methylphenyl)[1,3]thiazolo[4,5-*b*]pyridine (**12c**, 8.75 g, 65%). ¹H NMR (400 MHz, CDCl₃): δ_H 9.32 (s, 1H), 8.63 (s, 1H), 7.38-7.35 (m, 1H), 7.32-7.27 (m, 3H), 2.18 (s, 3H).



S16


^1H NMR (400 MHz, DMSO- d_6):



LC-MS:

3: UV Detector: TAC: Wavelength Range: (210 - 450)


1.429e+2
Range: 1.429e+2



Peak ID Time Mass Found
1 1.51 307

1: (Time: 1.51) Combine (204:211-183:196)


1: MS ES+
7.5e+007




Peak ID Time Mass Found
1 1.51 305

1: (Time: 1.51) Combine (204:211-182:196)

2: MS ES-
1.3e+006






1.2.3. General procedure for the synthesis of substituted 6-methyl-2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridines **7a–c**

The corresponding 6-bromo-5-phenyl[1,3]thiazolo[4,5-*b*]pyridine **13a–c** (4.56 mmol, 1.0 equiv), methylboronic acid (1.13 g, 18.24 mmol, 4.0 equiv), potassium phosphate (1.94 g, 9.12 mmol, 2.0 equiv), palladium(II) acetate (103 mg, 0.46 mmol, 0.1 equiv) and 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (579 mg, 1.37 mmol, 0.3 equiv) were consecutively dissolved in absolute toluene (40 mL) in a flame-dried round-bottom flask under argon. The resulting reaction mixture was stirred under reflux conditions for 3.5 h. After cooling to room temperature, water (80 mL) and toluene (20 mL) were added, followed by addition of ammonium pyrrolidinedithiocarbamate (328 mg, 2.00 mmol, 0.44 equiv). The reaction mixture was stirred for 1 h at room temperature, and the organic layer was washed with saturated aq NaHCO₃ solution, dried over anhydrous MgSO₄, filtered and concentrated under reduced pressure. The resulting crude residue was purified via column chromatography (gradient ethyl acetate/heptane) to afford the desired 5-phenyl-6-methyl[1,3]thiazolo[4,5-*b*]pyridine **5**, **15a** or **15c** as an intermediate. The corresponding 5-phenyl-6-methyl[1,3]thiazolo[4,5-*b*]pyridine **5**, **15a** or **15c** (1.23 mmol, 1.0 equiv) was dissolved in absolute toluene (10 mL) in a flame-dried round-bottom flask under argon. Ammonia borane (114 mg, 3.69 mmol, 3.0 equiv) and B(C₆F₅)₃ (32 mg, 0.06 mmol, 0.05 equiv) were added and the resulting reaction mixture was stirred at a temperature of 45 °C for 5 h and concentrated thereafter under reduced pressure. The remaining residue was redissolved in acetonitrile, formic acid was added, and the reaction mixture was stirred at room temperature for further 45 min. The phases were separated, and the organic layer was concentrated under reduced pressure. The resulting crude product was purified via column chromatography (gradient ethyl acetate/heptane) to afford the desired 5-phenyl-6-methyl-2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridine **7a–c**.

1.2.4. Characterization of substituted 6-methyl-2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridines **7a–c**




7a

6-Methyl-5-phenyl-2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridine (**7a**, 610 mg, 55%). ¹H NMR (600 MHz, CDCl₃): δ 2.08 (s, 3H), 4.30 (s, 2H), 7.03 (s, 1H), 7.31–7.35 (m, 2H), 7.40–7.41 (m, 4H) ppm; ¹³C NMR (CDCl₃, 151 MHz): δ 18.8 (CH₃), 48.6 (CH₂), 119.6 (C), 120.2 (C), 127.4 (CH), 128.1 (CH), 129.0 (CH), 130.5 (CH), 140.7 (C), 150.8 (C), 159.4 (C) ppm; HRMS (ESI, m/z): calcd. for C₁₃H₁₃N₂S, 229.0799 [M+H]⁺; found 229.0790.

3: UV Detector: TIC


4.278e+2
Range: 4.269e+2



Peak ID Time Mass Found
1 0.91 229.07

1: (Time: 0.91) Combine (119:126-93:106)


1: MS ES+
5.8e+007





Peak ID Time Mass Found
1 0.91 273.07, 227.07


1: (Time: 0.91) Combine (119:126-93:106)

2: MS ES-
1.2e+005










7b

5-(2-Fluorophenyl)-6-methyl-2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridine (**7b**, 630 mg, 62%). ^1H NMR (600 MHz, CDCl_3): δ 2.00 (s, 3H), 4.55 (s, 2H), 6.61 (brs, 1H), 7.07 (s, 1H), 7.09–7.12 (m, 1H), 7.19–7.21 (m, 1H), 7.32–7.36 (m, 2H) ppm; ^{13}C NMR (CDCl_3 , 151 MHz): δ 17.96 (CH_3), 17.99 (CH_3), 48.8 (CH_2), 115.6 (CH), 115.7 (CH), 121.0 (C), 121.8 (C), 124.15 (CH), 124.18 (CH), 129.59 (CH), 129.64 (CH), 130.2 (CH), 131.40 (CH), 131.43 (CH), 145.6 (C), 158.9 (C), 159.2 (C), 160.5 (C) ppm; HRMS (ESI, m/z): calcd. for $\text{C}_{13}\text{H}_{12}\text{FN}_2\text{S}$, 247.0705 $[\text{M}+\text{H}]^+$; found 247.0724.


3: UV Detector: TAC: Wavelength Range: (210 - 450)

1.771e+2
Range: 1.769e+2




Peak ID Time Mass Found
1 1.05 247
1: (Time: 1.05) Combine (141:147-116:129)


1:MS ES+
1.0e+008




Peak ID Time Mass Found
1 1.05 245
1: (Time: 1.05) Combine (140:147-115:129)

2:MS ES-
1.5e+005








7c

6-Methyl-5-(2-methylphenyl)-2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridine (**7c**, 212 mg, 52%). ^1H NMR (600 MHz, CDCl_3): δ 1.85 (s, 3H), 2.12 (s, 3H), 4.22 (s, 2H), 7.02 (s, 1H), 7.13 (d, $J = 7.2$ Hz, 1H), 7.19–7.26 (m, 3H), 7.69 (brs, 1H) ppm; ^{13}C NMR (CDCl_3 , 151 MHz): δ 17.8 (CH_3), 19.4 (CH_3), 48.5 (CH_2), 119.7 (C), 120.0 (C), 125.6 (CH), 127.6 (CH), 129.0 (CH), 129.9 (CH), 130.0 (CH), 136.1 (C), 140.2 (C), 151.0 (C), 159.3 (C) ppm; HRMS (ESI, m/z): calcd. for $\text{C}_{14}\text{H}_{15}\text{N}_2\text{S}$, 243.0956 $[\text{M}+\text{H}]^+$; found 243.0963.


3: UV Detector: TAC: Wavelength Range: (210 - 450)

1.834e+2
Range: 1.835e+2




Peak ID Time Mass Found
1 0.94 243
1: (Time: 0.94) Combine (116: 122-93: 105)


1: MS ES+
4.4e+007



Peak ID Time Mass Found
1 0.94 241
1: (Time: 0.94) Combine (116: 122-92: 105)

2: MS ES-
2.3e+005





159.32
150.99
140.20
136.10
129.98
129.96
129.04
127.64
125.64
119.98
119.67
77.23
77.02
76.81
48.53
19.44
17.79

CH3, CH

CH2, Cq

220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm


Scale: 6.956 ppm/cm, 1050 Hz/cm

Current Data Parameters
NAME 080411
EXPERNO 11
PROCNO 1
F2 - Acquisition Parameters
Date_ 20231021
Time_ 11:25 h
INSTRUM Avance Neo
PROBHD Z162398.0004 (1
PULPROG zgpg30
TD 65536
SOLVENT CDCl3
NS 2048
DS 4
SWH 35714.285 Hz
FIDRES 1.089913 Hz
AQ 0.915040 sec
RG 101
DE 18.00 usec
TE 298.1 K
CHST2 145.0000000
D1 2.00000000 sec
D12 0.0002000 sec
D16 0.00020000 sec
T00 1
SFO1 150.969723 MHz
NUC1 13C
P13 12.00 usec
F13 2000.00 usec
FNU0 117.1800234 MHz
SFOAL5 0.500
SFORES5 0 Hz
SFOF5 25.7849395 MHz
SFOF2 600.325403 MHz
NUC2 1H
CHST12 1.5000000
CDEPRG12 waltz164
P0 12.00 usec
P1 14.00 usec
P4 16.00 usec
PCPD2 80.00 usec
PWR2 5.55939994 W
PWR1 0.8198100 W
GRANM1 31.00 %
GRANM2 31.00 %
GRANM3 31.00 %
GR23 31.00 %
P16 1000.00 usec
F2 - Processing Parameters
SI 32768
SF 150.953102 MHz
WDW EM
SSB 0
GB 1.00 Hz
PC 1.40

1.2.5. General procedure for the synthesis of N-acylated 6-bromo-2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridines **14a–c**


The corresponding acid chloride (0.36 mmol, 1.1 equiv) and triethylamine (0.10 mL, 0.72 mmol, 2.2 equiv) were added to a stirred solution of the corresponding 6-bromo-5-phenyl-2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridine **13** (0.33 mmol, 1.00 equiv) in absolute dichloromethane (5 mL). The resulting reaction mixture was stirred at room temperature for 2 h, followed by dilution with dichloromethane and water, and subsequent extraction and phase separation. The aqueous layer was thoroughly extracted with dichloromethane, and the combined organic layers were dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure. The resulting crude product was purified via column chromatography (gradient ethyl acetate/heptane) to afford the desired target compounds **14a–c**.

1.2.6. Characterization of N-acylated 6-bromo-2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridines **14a–c**



14a

1-(6-Bromo-5-phenyl[1,3]thiazolo[4,5-*b*]pyridin-3(2*H*)-yl)ethanone (**14a**, 92 mg, 72%). ¹H NMR (600 MHz, CDCl₃): δ 2.65 (s, 3H), 5.35 (s, 2H), 7.39–7.47 (m, 3H), 7.65–7.66 (m, 1H), 7.66–7.70 (m, 2H) ppm; ¹³C NMR (CDCl₃, 151 MHz): δ 25.0 (CH₃), 49.9 (CH₂), 112.8 (C), 126.3 (C), 127.9 (CH), 128.7 (CH), 129.7 (CH), 134.6 (CH), 138.8 (C), 150.7 (C), 151.2 (C), 170.4 (C) ppm; HRMS (ESI, *m/z*): calcd. for C₁₄H₁₂BrN₂OS, 334.9854 [M+H]⁺; found 334.9854.





5.35

2.65

1.57

1.26




Current Data Parameters
NAME 079807
EXPNO 10
PROCNO 1


F2 - Acquisition Parameters
Date_ 20231019
Time 21:44 h
INSTRUM Avance Neo
PROBHD Z162398_0004 (PULPROG
TD 2930
FIDRES 131072
SOLVENT CDCl3
NS 0
DS 0
SWH 15625.000 Hz
FIDRES 0.238419 Hz
AQ 4.1943040 sec
RG 12.7
DW 32.000 usec
DE 10.00 usec
TE 300.2 K
TD0 1.00000001 sec
SFO1 600.3357031 MHz
NUC1 1H
P0 2.60 usec
F1 7.80 usec
PLW1 5.56960011 W

F2 - Processing Parameters
SI 131072
SF 600.3300157 MHz
WDW EM
SSB 0
LB 0.20 Hz
GB 0
PC 4.00


Scale 0.5152 ppm/cm, 309.3 Hz/cm

TMS line width: 0.06 Hz





Current Data Parameters
 NAME 079807
 EXPTNO 11
 PROCNO 1
 F2 - Acquisition Parameters
 Date_ 20231019
 Time 23:27 h
 INSTRUM Avance Neo
 PROBD Z162398_0004 (1
 PULPROG zgpg30
 SOLVENT CDCl₃
 NS 2048
 DS 0
 SWH 35714.285 Hz
 FIDRES 0.1975043 Hz
 AQ 0.3175043 sec
 RG 101
 DW 14.000 usec
 DE 18.00 usec
 TE 298.2 K
 TS 145.0000000
 CPDPRG2 1
 D1 2.00000000 sec
 D2 0.00344828 sec
 D12 0.0002000 sec
 D16 0.0002000 sec
 T1RHO 150.9697221 MHz
 NUCL1 13C
 P1 12.00 usec
 F13 2000.00 usec
 EPRG 117.1600034 W
 SFO2 25.7849985 W
 SFO5 600.3524013 MHz
 SFO15 0.500
 SFO755 0 Hz
 SPNS 25.7849985 W
 SPO2 600.3524013 MHz
 SPO15 0.500
 SPO755 0 Hz
 CPMRG12 1.5000000
 WALTZ16 12.00 usec
 P0 8.00 usec
 F3 12.00 usec
 PCPR2 80.00 usec
 PLW2 5.55999994 W
 PLW12 0.05560000 W
 GPRM(1) SINE,100
 GPRM(2) SINE,100
 GPRM(3) SINE,100
 GP23 31.00 %
 F16 1000.00 usec
 F2 - Processing parameters
 SI 32768
 SF 150.9530991 MHz
 EM 0
 SSB 0
 GB 1.00 Hz
 PC 1.40




14b

1-[6-Bromo-5-(2-fluorophenyl)[1,3]thiazolo[4,5-*b*]pyridin-3(2*H*)-yl]-2-methylpropan-1-one (**14b**, 22 mg, 17%). ¹H NMR (600 MHz, CDCl₃): δ 1.14 (d, *J* = 6.9 Hz, 6H), 3.95–4.00 (m, 1H), 5.35 (s, 2H), 7.15–7.25 (m, 2H), 7.38–7.45 (m, 2H), 7.64–7.66 (m, 1H) ppm; ¹³C NMR (CDCl₃, 151 MHz): δ 19.0 (CH₃), 32.8 (CH), 50.3 (CH₂), 114.8 (C), 115.8 (CH), 123.8 (CH), 127.3 (C), 127.6 (C), 130.6 (CH), 131.2 (CH), 133.9 (CH), 147.3 (C), 150.4 (C), 159.5 (d, C), 177.9 (C) ppm; HRMS (ESI, *m/z*): calcd. for C₁₆H₁₅BrFN₂OS, 381.0065 [M+H]⁺; found 381.0072.


3: UV Detector: TAC: Wavelength Range: (210 - 450)

4. 31e+1
Range: 4. 314e+1




Peak ID Time Mass Found
1 1.77 381
1: (Time: 1.77) Combine (219: 225-196: 208)


1: MS ES+
1. 1e+006




Peak ID Time Mass Found
1 1.77 Not Found
1: (Time: 1.77) Combine (219: 225-195: 208)

2: MS ES-
3. 0e+005








14c

1-[6-Bromo-5-(2-methylphenyl)[1,3]thiazolo[4,5-*b*]pyridin-3(2*H*)-yl]ethanone (**14c**, 51 mg, 73%). ¹H NMR (600 MHz, CDCl₃): δ 2.20–2.23 (m, 3H), 2.57 (s, 3H), 5.36–5.43 (m, 2H), 7.21–7.23 (m, 1H), 7.28–7.32 (m, 2H), 7.34–7.37 (m, 1H), 7.67–7.69 (m, 1H) ppm; ¹³C NMR (CDCl₃, 151 MHz): δ 19.6 (CH₃), 24.8 (CH₃), 49.8 (CH₂), 114.6 (C), 125.5 (CH), 126.5 (C), 128.6 (CH), 129.1 (CH), 130.1 (CH), 133.8 (CH), 135.9 (C), 139.1 (C), 150.4 (C), 152.7 (C), 170.5 (C) ppm; HRMS (ESI, *m/z*): calcd. for C₁₅H₁₄BrN₂OS, 349.0025 [M+H]⁺; found 349.0010.


3: UV Detector: TAC: Wavelength Range: (210 - 450)

2. 712e+2
Range: 2. 713e+2




Peak ID Time Mass Found
1 1.69 349
1: (Time: 1.69) Combine (209: 215-185: 197)


1: MS ES+
1. 4e+007




Peak ID Time Mass Found
1 1.69 Not Found
1: (Time: 1.69) Combine (209: 215-184: 197)

2: MS ES-
2. 6e+006








1.2.7. General procedure for the synthesis of N-acylated 6-methyl-2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridines 16a–f

The corresponding acyl chloride (0.31 mmol, 1.1 equiv) and triethylamine (0.09 mL, 0.63 mmol, 2.2 equiv) were added to a stirred solution of the corresponding 6-methyl-5-phenyl-2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridine **7a–c** (0.28 mmol, 1.00 equiv) in absolute DCM (5 mL). The resulting reaction mixture was stirred at room temperature for 30–120 min, followed by dilution with DCM and water, and subsequent extraction and phase separation. The aqueous layer was thoroughly extracted with DCM, and the combined organic layer was dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure. The remaining crude product was purified via column chromatography (gradient ethyl acetate/heptane) to afford the corresponding desired target compound **16a–f**.

1.2.8. Characterization of N-acylated 6-methyl-2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridines 16a–f




16a

1-(6-Methyl-5-phenyl[1,3]thiazolo[4,5-*b*]pyridin-3(2*H*)-yl)ethanone (**16a**, 150 mg, 94%). ¹H NMR (600 MHz, CDCl₃): δ 2.32 (s, 3H), 2.68 (s, 3H), 5.32 (s, 2H), 7.33 (s, 1H), 7.36–7.39 (m, 1H), 7.42–7.45 (m, 2H), 7.51–7.53 (m, 2H) ppm; ¹³C NMR (CDCl₃, 151 MHz): δ 19.7 (CH₃), 24.8 (CH₃), 49.2 (CH₂), 124.1 (C), 125.9 (C), 127.9 (CH), 128.1 (CH), 129.0 (CH), 139.9 (C), 149.6 (C), 151.8 (C), 170.5 (C) ppm; HRMS (ESI, *m/z*): calcd. for C₁₅H₁₅N₂OS, 271.0906 [M+H]⁺; found 271.0905.


3: UV Detector: TAC: Wavelength Range: (210 - 450)


3. 357e+2
Range: 3. 358e+2




Peak ID Time Mass Found
1 1.59 271
1: (Time: 1.59) Combine (197: 203-168: 181)

1: MS ES+
2. 7e+007





Current Data Parameters
NAME: 080412
EXPNO: 10
PROCNO: 1
F2 - Acquisition Parameters
Date_: 20231021
Time: 11.30 h
INSTRUM: Avance Neo
PROBHD: 5mm QNP 1H/13
PULPROG: zgpg30
TD: 131072
SOLVENT: CDCl3
NS: 8
DS: 4
SWH: 15623.000 Hz
FIDRES: 0.238419 Hz
AQ: 4.1943040 sec
RG: 12.7
DE: 2.000 usec
TE: 298.2 K
D1: 1.00000000 sec
TD0: 1
PRG1: 600.3357031 MHz
NUC1: 13C
P1: 7.80 usec
PL1: 5.56960011 W
F2 - Processing Parameters
SI: 111072
SF: 600.3300157 MHz
WDW: EM
SSB: 0
GB: 0
PC: 4.00




16b

2-Methyl-1-(6-methyl-5-phenyl[1,3]thiazolo[4,5-*b*]pyridin-3(2*H*)-yl)propan-1-one (**16b**, 130 mg, 72%). ¹H NMR (600 MHz, CDCl₃): δ 1.20 (d, *J* = 6.7 Hz, 6H), 2.32 (s, 2H), 4.15–4.19 (m, 1H), 5.32 (s, 2H), 7.33 (s, 1H), 7.37–7.39 (m, 1H), 7.43–7.45 (m, 2H), 7.51–7.53 (m, 2H) ppm; ¹³C NMR (CDCl₃, 151 MHz): δ 19.2 (2 × CH₃), 19.7 (CH₃), 32.6 (CH), 49.6 (CH₂), 124.3 (C), 125.8 (C), 127.8 (CH), 128.0 (CH), 129.0 (CH), 132.9 (CH), 139.9 (C), 149.4 (C), 151.8 (C), 177.9 (C) ppm; HRMS (ESI, *m/z*): calcd. for C₁₇H₁₉N₂OS, 299.1218 [M+H]⁺; found 299.1218.


3: UV Detector: TAC: Wavelength Range: (210 - 450)

4. 235e+2
Range: 4. 236e+2




Peak ID Time Mass Found
1 1.80 299
1: (Time: 1.80) Combine (224: 230-199: 211)


1: MS ES+
2. 7e+007




Peak ID Time Mass Found
1 1.80 Not Found
1: (Time: 1.80) Combine (223: 229-198: 211)


2: MS ES-
1. 1e+006









Current Data Parameters		NAME		080413	
XPOS		11		11	
YPOS		11		11	
F2 - Acquisition Parameters					
Date--		20231021			
Time--		1:00:00 h			
INSTRUM		Averana			
PROBHD		Z16239.0004 (
POLYFCG		deP4pGpP			
TD		65536			
SOLVENT		CDCl3			
NS		2043			
DS		0			
SWH		35714.285 Hz			
FIDRES		1.089913 Hz			
AQ		0.517010 sec			
DQ		14.000 usec			
DM		18.000 usec			
TE		298.1 K			
TR		145.000000 sec			
CHRG2		2.00000000 sec			
D2		0.0034858 sec			
D12		0.0002000 sec			
D16		0.0002000 sec			
SOL1		150.969293 MHz			
SOL2		13C			
MOL1		12.00 usec			
P1		12.00 usec			
P13		117.900032 M			
FIDM0		0.50000000 sec			
SNAME15		C13pmpc42			
SFOV25		0.500			
SFOV35		0.500			
SPW5		25.18493995 M			
MUC2		600.328231 MHz			
CHRG12		1.5000000			
CPORG12		M1264			
P2		12.00 usec			
P4		16.00 usec			
PCD2		80.00 usec			
FID2		5.55959994 M			
FID12		0.05160000 W			
CP11		S110.00 Hz			
GPM4(2)		S1H.100 Hz			
GPM4(3)		S1H.100 Hz			
GPM4(1)		S1H.100 Hz			
P16		1000.00 usec			
F2 - Processing parameters					
S1		357068 MHz			
WIN		150.959999 MHz			
DM		0			
S1B		0			
P8		1.00 Hz			
PC		1.40			





16c

1-[5-(2-Fluorophenyl)-6-methyl[1,3]thiazolo[4,5-*b*]pyridin-3(2*H*)-yl]ethanone (**16c**, 150 mg, 84%). ^1H NMR (600 MHz, CDCl_3): δ 2.16 (d, $J = 2.2$ Hz, 3H), 2.61 (s, 2H), 5.32 (s, 2H), 7.12–7.15 (m, 1H), 7.21–7.24 (m, 1H), 7.34 (s, 1H), 7.37–7.49 (m, 2H) ppm; ^{13}C NMR (CDCl_3 , 151 MHz): δ 18.41 (CH_3), 18.44 (CH_3), 24.7 (CH_3), 49.3 (CH_2), 115.7 (CH), 115.8 (CH), 124.09 (CH), 124.12 (CH), 125.2 (C), 127.8 (C), 129.9 (CH), 130.0 (CH), 131.37 (CH), 131.40 (CH), 132.1 (CH), 147.0 (C), 149.6 (C), 158.9 (C), 160.6 (C), 170.6 (C) ppm; HRMS (ESI, m/z): calcd. for $\text{C}_{15}\text{H}_{14}\text{FN}_2\text{OS}$, 289.0811 $[\text{M}+\text{H}]^+$; found 289.0806.










16d

1-[5-(2-Fluorophenyl)-6-methyl[1,3]thiazolo[4,5-*b*]pyridin-3(2*H*)-yl]-2-methylpropan-1-one (**16d**, 109 mg, 75%). ^1H NMR (600 MHz, CDCl_3): δ 1.15 (d, $J = 6.7$ Hz, 6H), 2.15 (d, $J = 1.9$ Hz, 3H), 4.08–4.11 (m, 1H), 5.32 (s, 2H), 7.13–7.16 (m, 1H), 7.22–7.25 (m, 1H), 7.34 (s, 1H), 7.36–7.41 (m, 2H) ppm; ^{13}C NMR (CDCl_3 , 151 MHz): δ 18.40 (CH_3), 18.43 (CH_3), 19.1 ($2 \times \text{CH}_3$), 32.5 (CH), 49.7 (CH_2), 115.6 (CH), 115.8 (CH), 124.08 (CH), 124.10 (CH), 125.3 (C), 127.66 (C), 127.7 (C), 127.8 (C), 129.86 (CH), 129.9 (CH), 131.38 (CH), 131.40 (CH), 132.2 (CH), 147.1 (CH), 149.4 (CH), 159.0 (C), 160.6 (C), 177.9 (C) ppm; HRMS (ESI, m/z): calcd. for $\text{C}_{17}\text{H}_{18}\text{FN}_2\text{OS}$, 317.1124 $[\text{M}+\text{H}]^+$; found 317.1109.


3: UV Detector: TAC: Wavelength Range: (210 - 450)


8.437e+1
Range: 8.449e+1





Peak ID Time Mass Found
1 1.78 317
1: (Time: 1.78) Combine (221: 227-196: 209)

1: MS ES+
1.1e+007








[illegible]




16e

1-[6-Methyl-5-(2-methylphenyl)[1,3]thiazolo[4,5-*b*]pyridin-3(2*H*)-yl]ethanone (**16e**, 150 mg, 84%). ¹H NMR (600 MHz, CDCl₃): δ 2.02 (s, 3H), 2.14 (s, 3H), 2.57 (s, 3H), 5.33 (s, 2H), 7.13 (d, *J* = 7.2 Hz, 1H), 7.22–7.31 (m, 3H), 7.34 (s, 1H) ppm; ¹³C NMR (CDCl₃, 151 MHz): δ 18.5 (CH₃), 19.6 (CH₃), 24.6 (CH₃), 49.2 (CH₂), 124.2 (C), 125.6 (CH), 126.7 (C), 127.9 (CH), 129.0 (CH), 130.2 (CH), 132.2 (CH), 135.9 (C), 139.5 (C), 149.3 (C), 152.8 (C), 170.6 (C) ppm; HRMS (ESI, *m/z*): calcd. for C₁₆H₁₇N₂OS, 285.1062 [M+H]⁺; found 285.1066.








Current Data Parameters
 NAME: 080416
 EXPRNO: 11
 PROCNO: 1



F2 - Acquisition Parameters
 Date_: 20231021
 Time: 20.20 h
 INSTRUM: spect
 PROBHD: 5 mm QNP 1H/13
 PULPROG: zgpg30
 TO: 65536
 SOLVENT: CDCl₃
 NS: 2046
 DS: 4
 SWH: 35714.285 Hz
 FIDRES: 1.089913 Hz
 AQ: 0.915040 sec
 TM: 14.000 usec
 DE: 18.00 usec
 TE: 298.1 K
 CHST2: 145.000000
 D1: 1.000000 sec
 D2: 0.00344828 sec
 D12: 0.0002000 sec
 D16: 0.0002000 sec
 TRO: 150.9697221 MHz
 NUC1: 13C
 P13: 12.00 usec
 PL3: 2000.00 usec
 FWH: 0 W
 SFO: 117.1600244 MHz
 SEQA15: C13P1300244
 SEQA15: 0.500
 SFOF55: 0 Hz
 SFOF55: 25.7849985 MHz
 NUC2: 1H
 NUC2: 600.324913 MHz
 CHST12: 1.5000000
 CPOH12: Waltz16
 P0: 12.00 usec
 P1: 18.00 usec
 P2: 16.00 usec
 PCPD2: 80.00 usec
 FWH2: 5.55599994 W
 SFOF11: 500.136051 MHz
 GPR1: 31.00 %
 GPR12: 31.00 %
 GPR13: 31.00 %
 GPR14: 31.00 %
 P15: 1000.00 usec


F2 - Processing parameters
 SI: 32768
 SF: 150.930942 MHz
 WDW: EM
 SSB: 0
 LB: 1.00 Hz
 GB: 0 Hz
 PC: 1.40




16f


2-Methyl-1-[6-methyl-5-(2-methylphenyl)[1,3]thiazolo[4,5-*b*]pyridin-3(2*H*)-yl]propan-1-one (**16f**, 145 mg, 74%). ^1H NMR (600 MHz, CDCl_3): δ 1.10 (d, $J = 6.7$ Hz, 6H), 2.01 (s, 3H), 2.13 (s, 3H), 5.33 (s, 2H), 4.08–4.12 (m, 1H), 5.33 (s, 2H), 7.12 (d, $J = 7.2$ Hz, 1H), 7.23–7.31 (m, 3H), 7.34 (s, 1H) ppm; ^{13}C NMR (CDCl_3 , 151 MHz): δ 18.5 ($2 \times \text{CH}_3$), 19.5 (CH_3), 32.3 (CH_3), 49.7 (CH_2), 124.4 (C), 125.6 (CH), 126.6 (C), 127.9 (CH), 129.0 (CH), 130.1 (CH), 132.2 (CH), 135.8 (C), 139.6 (C), 149.1 (C), 152.9 (C), 178.0 (C) ppm; HRMS (ESI, m/z): calcd. for $\text{C}_{18}\text{H}_{21}\text{N}_2\text{OS}$, 313.1375 $[\text{M}+\text{H}]^+$; found 313.1363.








1.2.9. Characterization of borylated compounds 17a–e and side product 17f



17a

In a dedicated additional synthesis complementing the optimization work outlined in Table 1 of the Main Manuscript, 6-methyl-5-phenyl[1,3]thiazolo[4,5-*b*]pyridine (**15a**, 3.07 mmol, 1.0 equiv) was dissolved in absolute toluene (10 mL) in a flame-dried round-bottom flask under argon. Ammonia borane (285 mg, 9.20 mmol, 3.0 equiv) and B(C₆F₅)₃ (79 mg, 0.15 mmol, 0.05 equiv) were added to the solution and the resulting reaction mixture was stirred at a temperature of 45 °C for 5 h and concentrated thereafter under reduced pressure. The remaining crude product was purified carefully via column chromatography (gradient ethyl acetate/hexane) to afford the borylated 2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridine **17a**.

3-Boryl-6-methyl-5-phenyl-2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridine (**17a**, 49 mg, 11%). ¹H NMR (400 MHz, CDCl₃): δ 1.63 (br s, 2H), 2.15 (s, 3H), 4.69–4.72 (m, 2H), 7.10–7.12 (m, 1H), 7.31–7.38 (m, 2H), 7.39–7.48 (m, 3H), 7.21–7.24 (m, 1H) ppm; HRMS (ESI, *m/z*): calcd. for C₁₄H₁₅BN₂S [M]⁺ 254.1049; found 254.1042.






3-Boryl-6-methyl-5-(2-fluorophenyl)-2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridine (**17b**, 78 mg, 83% purity, 18%). ¹H NMR (400 MHz, CDCl₃): δ 1.77 (s, 3H), 2.40-2.65 (br. d, 2H), 5.05-5.12 (m, 2H), 6.89-6.91 (m, 1H), 7.08-7.25 (m, 3H), 7.32–7.48 (m, 1H) ppm; HRMS (ESI, m/z): calcd. for C₁₃H₁₂BFN₂S [M]⁺ 258.0798; found 258.0805.





3-Boryl-6-methyl-5-(2-methylphenyl)-2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridine (**17c**, 61 mg, 12%). ¹H NMR (400 MHz, CDCl₃): δ 2.03 (s, 3H), 2.31 (s, 3H), 2.51 (br s, 2H), 5.11–5.15 (m, 2H), 6.87–6.89 (m, 1H), 7.10–7.18 (m, 3H), 7.21–7.24 (m, 1H) ppm; HRMS (ESI, m/z): calcd. for C₁₄H₁₅BN₂S [M]⁺ 254.1049; found 254.1042.








17d

6-Bromo-5-(2-methylphenyl)[1,3]thiazolo[4,5-*b*]pyridine (3.07 mmol, 1.0 equiv) was dissolved in absolute toluene (10 mL) in a flame-dried round-bottom flask under argon. Ammonia borane (285 mg, 9.20 mmol, 3.0 equiv) and $\text{B}(\text{C}_6\text{F}_5)_3$ (79 mg, 0.15 mmol, 0.05 equiv) were added to the solution and the resulting reaction mixture was stirred at a temperature of 45 °C for 5 h and concentrated thereafter under reduced pressure. The remaining residue was redissolved in acetonitrile, formic acid was added, and the reaction mixture was stirred at room temperature for 2 h. The phases were separated via phase separator and the organic layer was concentrated under reduced pressure. The remaining crude product was purified via column chromatography (gradient ethyl acetate/hexane) to afford the desired substituted 6-bromo-2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridine **13c**. As this reduction was subject to a detailed optimization, borylated intermediates **17d**, **17e** and arylated side product **17f** could be isolated in several cases depending on the reaction conditions.


3-Boryl-6-bromo-5-(2-methylphenyl)-2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridine (**17d**, 179 mg, 29%). ^1H NMR (600 MHz, CDCl_3): δ 2.14 (s, 3H), 2.51 (brs, 2H), 5.11–5.14 (m, 2H), 7.01–7.05 (m, 1H), 7.10–7.12 (m, 1H), 7.22–7.25 (m, 2H), 7.30–7.34 (m, 1H) ppm; ^{13}C NMR (CDCl_3 , 151 MHz): δ 19.4 (CH_3), 56.8 (CH_2), 104.0 (C), 125.6 (CH), 128.3 (CH), 128.9 (CH), 129.0 (CH), 129.7 (CH), 131.0 (C), 136.3 (C), 136.4 (C), 144.3 (C), 157.5 (C) ppm; HRMS (ESI, m/z): calcd. for $\text{C}_{13}\text{H}_{12}\text{BBBrN}_2\text{S}$ [M] $^+$ 317.9997; found 317.9982.













5-(2-Fluorophenyl)-6-pentafluorophenyl-2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridine (**17f**, 24 mg, 2%). ^1H NMR (400 MHz, CDCl_3): δ 2.20 (s, 3H), 4.55 (s, 2H), 6.58 (br. s, 1H, NH), 7.16-7.18 (m, 1H), 7.21–7.31 (m, 4H) ppm; HRMS (ESI, m/z): calcd. for $\text{C}_{19}\text{H}_{11}\text{F}_5\text{N}_2\text{S}$ $[\text{M}]^+$ 394.0563; found 394.0552.





2. Biology and biochemistry

2.1. In vivo greenhouse screening

Seeds of mono- and dicotyledonous weed plants and crop plants were sown in plastic or organic planting pots in sandy loam and covered with soil (replicates: $n = 10$, i.e., 10 monocotyledonous weed seeds were grown per pot or $n = 5$, i.e., 5 dicotyledonous weed seeds were grown per pot). The 2,3-dihydro[1,3]thiazolo[4,5-*b*]pyridines described above (e.g., **7a–c**, **13a–c**, **14a–c**, **16a–f**, and **17a–b**), formulated in the form of wettable powder (WP), were applied to the surface of the covering soil as aqueous suspension or emulsion, with the addition of 0.5% of an additive at an application rate of 600 L of water/ha (converted). Following treatment, the pots were placed in a greenhouse and kept under optimum growth conditions for the test plants. The test plants were placed in the greenhouse for ca. three weeks under optimum growth conditions, and then the effect of the preparations was assessed visually in comparison to untreated control plants (herbicidal effect: 100% = plants died off, 0% = as untreated control plants). Efficacy values were given based on a rating scale by final visual experts' assessment of green mass, i.e., 5 \geq 90% inhibition, 4 = 70–89% inhibition, 3 = 50–69% inhibition, 2 = 40–49% inhibition, 1 = 21–39% inhibition, and — < 20% inhibition. Advanced screening was carried out with or as emulsifiable concentrate formulations, three replicate pots, and a standardized number of seeds per pot depending on the plant species (10 seeds for corn and wheat spectrum). The harmful plants and crops used in greenhouse tests were the following species: *Alopecurus myosuroides* (ALOMY), resistant *Alopecurus myosuroides* (ALOMY_R, origin: Germany), *Apera spica-venti* (APESV), *Brachiaria platyphylla* (BRAPP), *Bromus tectorum* (BROTE), *Echinochloa crus-galli* (ECHCG), *Digitaria sanguinalis* (DIGSA), *Eleusine indica* (ELEIN), *Glycine max* (GLXMA), *Lolium rigidum* (LOLRI), *Lolium sp.* (LOLSS), resistant *Lolium sp.* (LOLSS_R, origin: France), *Poa annua* (POAAN), *Setaria viridis* (SETVI), *Sorghum halepense* (SORHA), *Triticum aestivum* (TRZAS), and *Zea mays* (ZEAMX).

2.2. Biochemistry

2.2.1. *LpFAT A* expression and purification

The *fat a03* gene from *Lemna paucicostata*, in which the N-terminal amino acids representing the chloroplast transit peptide were replaced by an N-terminal 6xHis-tag, was cloned into a pET24 vector [1]. The *LpFAT A* protein was expressed in *E. coli* BL21Star(DE3) cells. 5 mL of an overnight culture of *E. coli* cells grown in LB medium with 100 µg/mL carbenicillin were used to inoculate 0.5 L of autoinduction medium containing 100 µg/mL carbenicillin [2]. The bacteria were grown at 37 °C and 120 rpm for about 4.5 h to reach $OD_{600} = 0.6$ and then further cultivated at 21 °C overnight. The bacteria were harvested by centrifugation (20 min, 6,000 g) and stored frozen at –80 °C. *LpFAT A* protein was purified using the Ni-NTA Fast Start Kit (Qiagen GmbH, Germany) according to the instructions of the manufacturer. Active fractions were pooled together, and the buffer was exchanged into 25 mM potassium phosphate buffer pH 7.3 containing 10% glycerol with PD10 columns (GE Healthcare). Aliquots of the protein solution were frozen in liquid nitrogen and stored at –80 °C.

2.2.2. *LpFAT A* fluorescence polarization assay

Fluorescence polarization (FP) competition assays were performed at room temperature in black 96-well microtiter plates (Greiner, Catalog No. 655900). The assay mixture contained 25 mM potassium phosphate buffer pH 7.3, 200 mM NaCl, 0.01% Triton X-100, 2 nM fluorescent tracer, 0.4 µg of purified *LpFAT A* protein and different amounts of the test compound in a total volume of 100 µL. FP was measured with a BMG CLARIOstar microtiter plate reader using the FP filter set for fluorescein (Ex 482-16, Em 530-40, LP504). FP is the difference between wells containing *LpFAT A* and wells containing only tracer. The pI_{50} values were calculated from plots of inhibition values vs test compound concentration using Model 205 of the ID Business Solutions Ltd Xlfit software suite. The *FAT A* binding fluorescent tracer was synthesized from (2*S*,4*S*)-4-[(2,6-difluorophenyl)methoxymethyl]-4-ethyl-2-methyl-*N*-(prop-2-ynylcarbamoyl)-1,3-dioxolane-2-carboxamide [1] and FAM azide, 5-isomer (Broadpharm BP-22544, San Diego, CA) by click chemistry [3] and was purified by flash column chromatography on silica gel.

3. References

- [1] Campe R, Hollenbach E, Kämmerer L, Hendriks J, Höffken H W, Kraus H, Lerchl, J, Mietzner, T, Tresch, S, Witschel, M, Hutzler, J. A new herbicidal site of action: Cinmethylin binds to acyl-ACP thioesterase and inhibits plant fatty acid biosynthesis. *Pesticide Biochemistry and Physiology* **148**: 116–125 (2018).
- [2] Studier F W. Protein production by auto-induction in high-density shaking cultures. *Protein Expr. Purif.* **41**: 207-234 (2005).
- [3] Punna S, Kaltgrad E, Finn M G. “Clickable” Agarose for Affinity Chromatography. *Bioconjugate Chem.* **16**: 1536-1541 (2005).